TEM— AI Stock Forecast & Price Targets
Published 7/28/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live TEM price forecast →
Tempus AI faces a binary Q2 earnings event with significant technical weakness and high short interest, but strategic acquisitions (Personalis) and product launches (OneOme) offer growth catalysts. The stock is pinned near 52-week lows with negative cash flow and debt pressures, yet recent Cathie Wood buying and positive news on integration provide counterbalance.
Wait for earnings (July 30) — if price holds above $41.73, consider a small position; invalidation is break below $38.50. Avoid trading into the event due to high short float and binary nature of print.
Hold through Q2 print with focus on gross margin trajectory (target: 65%+). Catalysts include OneOme adoption metrics and Personalis integration progress; if revenue accelerates beyond $1.4B, re-evaluate upside. Invalidation is sustained below $38.50.
Long-term thesis hinges on successful monetization of Insights data licensing and scaling MRD testing to capture the multi-tens-of-billions TAM. Structural risk is dilution from Personalis deal; if cash burn improves by 20% annually, consider re-rating to $65+.
Revenue growth is strong (Q1 +36% sequential, 70% Y/Y TTM) but margins remain deeply negative (-22.2% profit margin), with operating cash flow at -$185M and gross margins at 62.2%. The $1.5B Personalis acquisition adds MRD testing capability but introduces dilution risk (31.7% short float). Debt-to-equity is high (316.6) and free cash flow negative, though gross margins are healthy at 62-64%, suggesting potential leverage if SG&A stabilizes.
The chart shows a downtrend with price pinned near the $41.73 52-week low, breaking below SMA20 (-21.25%) and SMA50 (-16.10%). The Kronos AI forecast band (yellow) suggests a potential rebound to $61.156 but is heavily discounted due to directional accuracy of only 17% for 1d forecasts. Technicals are bearish with RSI at 33.38, indicating oversold conditions but not enough momentum to reverse the downtrend immediately.
Key news includes Cathie Wood's $8.7M buy during a 14% weekly drop and the $1.5B Personalis acquisition (July 20), which adds Medicare-reimbursed MRD testing. However, negative sentiment dominates retail channels with phrases like 'epic shit show' on StockTwits. Earnings are binary with Q2 AMC imminent, but the stock remains pinned near 52-week lows despite positive product launches.
- $1.5B acquisition of Personalis for Medicare-reimbursed MRD testing (July 20)
- National launch of OneOme pharmacogenomics solution (July 22) with expanded dosing/toxicity TAM
- High dilution risk from $1.5B all-stock deal impacting pro-forma share count
- Persistent negative operating cash flow and high debt load ($1.32B) increasing probability of dilutive capital raises
- Technical breakdown near $41.73 with 28.5% short float creating gap risk
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord